Compare Abeona Therapeutics Inc (ABEO) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Centrus Energy Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Centrus Energy Corp trades at $185.86 (market cap $3.77B). The key difference: Centrus Energy Corp is far larger — about 9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | LEU | |
|---|---|---|
Market Cap | $421.19M | $3.77B |
Sector | Health | Energy |
52-Week High | $7.45 | $436.00 |
52-Week Low | $4.17 | $146.61 |
Enterprise Value | $276.10M | $3.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Centrus Energy (LEU) trades at $185.06, down 2.26% on the day, with a bullish technical signal from moving averages and a neutral RSI near 61. The stock shows strong earnings beats in Q1 and Q2 2026 but missed in Q4 2025, with revenue growth to $474 million in 2026. Recent news highlights a $4.5 billion backlog and a $1 billion DOE contract for nuclear fuel supply, positioning the company in the expanding nuclear energy sector.
Outlook is positive due to government support and contract wins, but risks include margin compression and high valuation multiples. Analysts maintain a buy consensus with a $228.50 price target, suggesting 23% upside, though execution on production goals by 2029 is critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
